DKSH Business Unit Healthcare, the leading partner for healthcare companies seeking to grow their business in Asia and beyond, will offer complete vaccine cold chain solutions for Medigen, a biopharmaceutical company in Taiwan. The range of services will include storage, distribution, delivery as well as value-added services, such as labeling and repackaging. Together with a dedicated healthcare delivery team covering all regions of Taiwan, DKSH will be providing storage in a two-to-eight-degree Celsius environment for Medigen’s temperature-sensitive COVID-19 vaccines in the company’s brand-new cold chain facility. The cold chain facility is certified by the Ministry of Health and Welfare’s Pharmaceutical Inspection Co-operation Scheme for Good Manufacturing and Distribution Practices (PIC/S GMP and PIC/S GDP) licenses to ensure the quality of the product is protected throughout the entire supply chain process.
Leo Lee, Executive Vice President of Medigen, indicated: “DKSH Taiwan has been serving the healthcare industry for more than 20 years. With a highly professional, dedicated team and an extensive healthcare supply chain network covering hospitals, clinics and all levels of healthcare service outlets, we are confident that DKSH will speedily and reliably deliver the vaccine to the right locations for people to be vaccinated in a timely manner.” Wennie Chang, Vice President, Business Unit Healthcare, DKSH Taiwan, shared: “Medigen’s successful development of COVID-19 vaccines has established a remarkable milestone in the biotechnology industry. It is our great honor to work with Medigen to contribute to the goal of healthcare for all and help our society alleviate the impacts of the pandemic.”
In addition to the brand-new cold chain facility, DKSH has a PIC/S GDP and PIC/S GDP certified multi-temperature healthcare distribution center and two depots, all supported by a dedicated healthcare delivery team.
About Medigen Vaccine Biologics Corporation
Medigen Vaccine Biologics Corporation (also known as MVC) is a biopharmaceutical company focusing on the development and production of vaccines and biologics. MVC has established a foothold in Taiwan and given priority to developing innovative pharmaceutical products for unmet medical needs. Meanwhile, MVC is dedicated to not only becoming the vaccine development and supply hub of the Asia-Pacific region but also protecting human health globally from the threats of various diseases.
DKSH’s purpose is to enrich people’s lives. For more than 150 years, we have been delivering growth for companies in Asia and beyond across our Business Units Healthcare, Consumer Goods, Performance Materials and Technology. As a leading Market Expansion Services provider, we offer sourcing, market insights, marketing and sales, eCommerce, distribution and logistics as well as after-sales services. Listed on the SIX Swiss Exchange, DKSH operates in 36 markets with 32,450 specialists, generating net sales of CHF 10.7 billion in 2020. The DKSH Business Unit Healthcare distributes pharmaceuticals, consumer health and over-the-counter (OTC) products as well as medical devices. With around 7,970 specialists, the Business Unit generated net sales of CHF 5.4 billion in 2020.